Technology | September 27, 2011

Varian Enhances TrueBeam, Introduces New Innovations at ASTRO

September 27, 2011 – Continual visual verification that a tumor is being accurately targeted during a radiotherapy treatment is now possible with recent enhancements to the TrueBeam system. This capability, called intrafraction motion review (IMR), is among the innovations that Varian Medical will showcase at this year's annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami Beach next week.

With intrafraction motion review, clinicians can use the imager on a TrueBeam system to continually monitor tumor location during treatment to ensure that the tumor hasn't moved out of range due to changes in the patient's breathing pattern.

"By introducing intrafraction treatment imaging and combining it with the millisecond response time of the TrueBeam machine, we can minimize the effects of changes in tumor motion during treatment," said Chris Toth, senior director of marketing for the company.

Varian will exhibit the company's full spectrum of products for planning and delivering image-guided radiotherapy and proton therapy, with a special emphasis on recent enhancements to its devices and software products, including:

  • A motion management interface for the Trilogy machine that enables integration with the Calypso system for tracking the prostate gland during treatment, for greater targeting accuracy.
  • A new user-centric design for the Aria oncology information system, with more personalization to the user, easy-to-follow task-driven workflows, greater automation and a single clinical management system that accesses both Aria and Varian's Eclipse treatment planning system from a single unified dashboard.
  • A new Aria iPad application that allows clinicians greater mobility.
  • New tools for using different types of images, including magnetic resonance (MR) images, to adapt a patient's treatment plan if there have been anatomical changes such as tumor shrinkage or weight loss during a multiple-week course of treatment.
  • A new version of Varian's BrachyVision software for planning brachytherapy treatments that is now fully integrated with the Aria oncology information system (OIS) for seamless management of patient data information.
  • A specially-designed treatment couch attachment that enables breast cancer treatments with the patient in the prone position to help minimize radiation exposure to heart and lung tissue and facilitates the use of RapidArc radiotherapy in the treatment of some breast cancer cases.

Several products in the development pipeline which have been submitted to the U.S Food and Drug Administration (FDA) for review will also be on display, including:

  • Higher dose delivery rates on the company's Trilogy and Clinac iX machines, for delivering high dose treatments more quickly to shorten treatment times and increase clinical efficiency.
  • New contouring tools that expedite treatment planning by using "smart" software to automatically identify and outline organs and other structures within diagnostic images and that enable clinicians to draw on a library of pre-contoured images by expert radiation oncologists and use these as a starting point for creating new treatment plans.

"Each of these innovations was designed to enable clinicians to make optimal treatment choices for their patients. By facilitating accurate, efficient treatments, these advances in Varian technology can help clinicians tackle even the most complex cases with confidence," said Toth. "Varian is committed to providing cancer treatment professionals with the best possible tools and devices for helping patients fight cancer."

For more information: www.varian.com

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Overlay Init